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A B S T R A C T
A patient with idiopathic CD4 T-lymphopenia was diagnosed with a recurrent disseminated
Mycobacterium avium infection. Because of progressive disease, treatment with interferon-gamma
(IFN-g) and interleukin-2 (IL-2) was started. The patient was successfully treatedwith IFN-g-1b and IL-2
in addition to anti-mycobacterial combination therapy. To our knowledge, this is the ﬁrst report of
successful combination therapy with IFN-g-1b and IL-2 in a patient with idiopathic CD4 T-lymphopenia.
Short-term IFN-g-1b and IL-2 might be considered as therapeutic options in refractory mycobacterial
infections in patients with idiopathic CD4 lymphopenia.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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We report the case of a patient with idiopathic CD4 T-
lymphopenia who was diagnosed with recurrent disseminated
Mycobacterium avium infection.
2. Case report
A 64-year-old man presented to our clinic in October 2004 with
progressive pain in his right upper leg and hip for 4 weeks without
history of trauma. He reported reduced general health, loss of
appetite, weight loss (5 kg), and low-grade fever for severalmonths.
2.1. Past medical history
In 1956, at the age of 16, the patient had had a bicycle accident
resulting in an injury to his left elbow, leading to a chronic skin
lesion with destructive bone involvement. The elbow joint had to
be treated surgically in 1964 and 1965. Mycobacterium para-
scrofulaceum had been identiﬁed as the causative agent.
The patient reported recurrent episodes of pneumonia, herpes
simplex labialis and herpes zoster. In December 1994, a squamous* Corresponding author.
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a tumor relapse had been successfully treated. In 1995, a
spinocellular carcinoma growing from the scar of the elbow
wound had been removed. In 1999, ﬁve basal cell carcinomas of the
nose had been treated. The family history was unrevealing.
There had been an osteodestructive infection of the thoracic
vertebrae and pleural cavity with Mycobacterium avium-intra-
cellulare (MAI) in December 2002. The patient had been
successfully treated according to resistance testing for 12
months; treatment had been stopped 12 months prior to the
current admission.
2.2. Investigations
This 64-year-old male patient was in a reduced general status
(175 cm, 62 kg, body mass index 20 kg/m2) with a herpes simplex
labialis lesion and pain over the right os ileum and trochanter
major as well as pain of the right hemithorax.
2.2.1. Laboratory parameters
Parameters of inﬂammation (C-reactive protein, erythrocyte
sedimentation rate) were increased. Alkaline phosphatase and
g-glutamyltransferase were elevated. A blood count showed
hypochromic microcytic anemia with reduced iron level. There
was marked thrombocytosis, lymphopenia and eosinophilia. The
T-lymphocyte count (CD3) and CD4 cell count were reduced andses. Published by Elsevier Ltd. All rights reserved.
Table 1
Laboratory parameters at admission in October 2004
Parameter Normal range
Leukocytes 9.5 4–11109/l
Lymphocytes 16 25–40%
Eosinophils 10 2–4%
Hemoglobin 11.4 14–18 g/dl
Mean corpuscular volume (MCV) 81 80–96 ﬂ
Thrombocytes 546 150–400109/l
T-lymphocyte count 587 690–2540/ml
CD4 cell count 254 410–1590/ml
CD4/CD8 ratio 0.8 1.0–5.8
Ferritin 120 30–200mg/l
Iron 20 80–150mg/dl
C-reactive protein (CRP) 15.6 <0.5 mg/dl
Erythrocyte sedimentation rate (ESR) 130 <20 mm/60 min
Alkaline phosphatase (AP) 350 <135 U/l
g-Glutamyltransferase (GGT) 150 <66 U/l
IgE 446 <100 IU/l
IgG 1266 700–1600 mg/dl
IgA 200 70–400 mg/dl
IgM 52 40–230 mg/dl
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increased; other immunoglobulins (IgG, IgA, IgM) and IgG
subclasses showed no abnormalities. Common variable immu-
nodeﬁciency syndrome (CVID) could be excluded (Table 1).
There was a normal lymphocyte stimulation test with
mitogens (PHA, PWM, SAC, ConA, OKT3) and antigens (tetanus,
diphtheria, streptolysin O, mumps), as well as a normal
granulocyte function test (myeloperoxidase staining, nitroblue
tetrazolium test, chemiluminescence, chemotaxis, oxidative
burst dihydrorhodamine test). Defects of the interferon-gamma
(IFN-g)–interleukin (IL)-12 axis were ruled out by normal IFN-g
production and IL-12, as well as IFN-g response to stimulation
with bacillus Calmette–Gue´rin. HIV serology and HIV PCR were
negative.
2.2.2. Radiologic ﬁndings
A computed tomography (CT) scan showed multiple new
osteolytic lesions of the pelvis, femoral bone, lumbar spine, and
the ribs. Several abscess-like osteoblastic–osteodestructive
lesions of the os ileum and os sacrum were demonstrated.
There was hepatosplenomegaly with multiple hypodense
lesions of the spleen; mediastinal and abdominal lymph nodes
were enlarged.
2.2.3. Bone biopsy
Histological work-up showed a plasma cell-rich granuloma-
tous inﬂammation with osteoblastic bone growth and osteo-Figure 1. CD4 cell count (dotted line indicating start and end of interferon-sclerosis. MAI was isolated by culture from the bone biopsy of the
pelvis.
2.3. Diagnosis
Recurrent disseminated MAI infection in a patient with
idiopathic CD4 T-lymphopenia (ICL) was diagnosed.1
2.4. Management
An anti-mycobacterial treatment was initiated in October 2004
with ethambutol, clarithromycin, and rifabutin, according to
resistance testing. Oral iron substitution was started. After three
months, there was only a small improvement in symptoms.
Parameters of inﬂammation were still elevated and a CT scan
showed progression of the osteolytic lesions.
The progressive disease with bony lesions leading to instability
of the pelvis, persistent immunosuppression due to the ICL, and the
MAI recurrence after one year of treatment, led to an additional
IFN-g treatment, as suggested by a previous report.2
Our aim was to accelerate the healing process using IFN-g,
despite the fact that therewas no proven interferon-based immune
defect. The ﬁrst cycle of IFN-g-1b was administered subcuta-
neously (90 mg (50 mg/m2), 3 times a week; Imukin1, Boehringer
Ingelheim) in February 2005; therapy cycles were continued
weekly. Therewas a progressive decline in the relevant parameters
(C-reactive protein, alkaline phosphatase, thrombocyte count), but
despite a slight improvement in symptoms, a CT scan in April 2005
showed progressive osteolytic lesions, and an abscess of the left os
ileumhad to be drained. Culture of the drained puswas positive for
MAI.
After ﬁvemonths ofMAI therapy in combinationwith IFN-g-1b,
clinical treatment response was questionable. Therefore we
decided to use Interleukin-2 (IL-2) for stimulation of CD4-cell
recovery. The ﬁrst cycle of IL-2 for 5 consecutive days (2  1.5 Mio
IU s.c., Proleukin-S1, Chiron) was administered in July 2005. From
the fourth day the dose was increased (2  3 Mio. IU). Further two
cycles were given in October and December 2005 (2  4.5 Mio. IU).
During the IL-2 cycles, IFN-g-1b injections were interrupted and
continued thereafter. MAI treatment was not interrupted at any
time.
After the ﬁrst cycle of IL-2, there was a marked improvement in
symptoms, laboratory parameters, and radiologic ﬁndings. The
patient’s pain score (analogue scale, 10 = ‘worst pain’, 0 = ‘no pain’)
dropped from 10 in April 2005 to 4 in November 2005. A CT scan in
January 2006 showed no more abscesses, but osteolytic lesions
remained with no further progression.
In February 2006, after one year, IFN-g-1b injections were
stopped. The patient’s body weight increased to 66 kg andgamma-1b treatment, arrows indicating interleukin-2 therapy cycles).
Figure 2. C-reactive protein (dotted line indicating start and end of interferon-gamma-1b treatment, arrows indicating interleukin-2 therapy cycles).
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mycobutin in February 2007 and stopped in December 2007.
Follow-up CT scans in July 2006, February 2007, and February 2008
showed stable results.
From February 2005, there was a decrease in inﬂammatory
parameters following IFN-g-1b treatment. There was a further
decline after the ﬁrst cycle of IL-2 in July 2005. Absolute CD4 cell
count and percentage of CD4 cell count increased after IL-2
treatment, and each IL-2 cycle was followed by an increase in CD4
cell count. There was a further increase in the absolute CD4 cell
count after stopping immunostimulating therapy according to an
increased lymphocyte count; the percentage of CD4 cells did not
change signiﬁcantly (Figures 1 and 2).
3. Discussion
Idiopathic CD4 lymphopenia is deﬁned as a CD4 T-lymphocyte
count of less than 300 cells/ml or less than 20% of total T-cells on
more than one occasion, in the absence of HIV infection and any
other immunodeﬁciency or therapy associated with depressed
levels of CD4 T-cells. The most frequent opportunistic infections in
ICL are cryptococcosis andMAI. Human papilloma virus infections,
dermatomal zoster and dermal malignancies are common.3,4
Therapeutic options include the treatment of opportunistic
infections and antibiotic prophylaxis when the CD4 cell count
falls below 200 cells/ml.
It has been shown that in some ICL patients, the administration
of IFN-g can lead to improvements in cellular immunity and
potentiation of the release of endogenous IFN-g and tumor
necrosis factor-alpha. The improved cellular immune response
may potentiate the effect of anti-mycobacterial therapy resulting
in a faster clinical recovery.2
Application of IL-2 in HIV-infected patients has been shown
to induce an increase in CD4 cells.5,6 One report described a
patient with ICL and pulmonary MAI infection successfully
treated ﬁrst with IFN-g for nine months and subsequently with
IL-2 for ﬁve years, in combination with antibiotics.7 Another ICL
patient with recurrent herpes zoster and gastrointestinal
candidiasis was treated successfully with IFN-g for 3 months
and subsequently with IL-2 for 5 months, in combination with
antiviral treatment.8
We cannot rule out that our treatment success was a result of
MAI treatment alone. The sustained treatment success in
contrast to the prior therapy in 2003 might also be explained
by the prolonged duration of MAI treatment. Nevertheless, we
noticed an acceleration in the healing process clinically and
improvement in the laboratory parameters after IFN-g-1b
and subsequent IL-2 treatment. The course of the disease was
highly suggestive of a beneﬁcial effect of IFN-g and IL-2. IL-2treatment resulted in a directly associated increase in CD4 cell
count.
Despite IL-2 treatment, the CD4 cell count was still below the
normal range during the time of active infection and up until 2008
when the patient was free from any signs of infection. A direct
association between CD4 cell count and the occurrence of MAI
infection was not obvious, conﬁrming previous ﬁndings.9,10 In
contrast to the report mentioned,7 we administered only three
short-term cycles of IL-2 during active MAI infection, and IFN-g
treatment was continued for one year. Since the end of the
immunostimulating treatment two years ago, there has been no
recurrence of MAI infection. Therefore, the short-term use of IFN-
g-1b and IL-2 during active disease might be sufﬁcient to
overcome an otherwise refractory infection and might be safely
discontinued despite the persistence of ICL.
4. Conclusions
A patient with ICL and a recurrent disseminatedMycobacterium
avium infection previously described by our group,1 was success-
fully treated with IFN-g-1b and IL-2 in addition to anti-
mycobacterial combination therapy. Therapy was well tolerated.
Short-term IFN-g-1b and IL-2 might be considered therapeutic
options in refractory mycobacterial infections in patients with
idiopathic CD4 lymphopenia.
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